J&J, U.S. government plan one billion doses of coronavirus vaccine By Reuters

© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company’s listing at the NYSE in New York

By Reuters Staff

(Reuters) – Johnson & Johnson said on Monday it made a $1 billion deal with the U.S. government to create enough manufacturing capacity for more than 1 billion doses of a vaccine it is testing to fight the new coronavirus that has killed more than 34,000 people around the world.

Johnson and Johnson said that it had selected its own lead vaccine candidate and would start human testing of its experimental coronavirus vaccine by September, with an eye on having it ready for emergency use in early 2021, the drugmaker said on Monday.

J&J said that the first batches of a vaccine could be available under an emergency use authorization in early 2021, far quicker than the typical 18 month period that it takes for vaccines to be tested, approved and then manufactured.

J&J also committed more than $1 billion of investment along with U.S. agency Biomedical Advanced Research and Development Authority (BARDA) to co-fund vaccine research, expanding a previous collaboration.

The new coronavirus, which emerged in Wuhan, China, has infected people in most countries around the world. The United States now has the most confirmed cases globally and many of them are in New York, where hospitals are reporting a scarcity of resources to treat the COVID-19 respiratory disease it causes.

A patient was dosed with Moderna Inc’s vaccine in an early-stage trial earlier this month, making it the front-runner in the race to develop a viable vaccine.

J&J said in January it had begun working on a possible vaccine for the coronavirus, using the same technologies used to make its experimental Ebola vaccine.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*